


(4-NH₂)-Exatecan

Cat. No.:	HY-145397
CAS No.:	2495742-21-5
Molecular Formula:	C ₂₃ H ₂₁ N ₃ O ₄
Molecular Weight:	403.43
Target:	Topoisomerase
Pathway:	Cell Cycle/DNA Damage
Storage:	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (247.87 mM; Need ultrasonic)																					
	<table border="1"> <thead> <tr> <th rowspan="2">Solvent</th> <th rowspan="2">Mass</th> <th colspan="3">Concentration</th> </tr> <tr> <th>1 mg</th> <th>5 mg</th> <th>10 mg</th> </tr> </thead> <tbody> <tr> <td rowspan="3">Preparing Stock Solutions</td> <td>1 mM</td> <td>2.4787 mL</td> <td>12.3937 mL</td> <td>24.7874 mL</td> </tr> <tr> <td>5 mM</td> <td>0.4957 mL</td> <td>2.4787 mL</td> <td>4.9575 mL</td> </tr> <tr> <td>10 mM</td> <td>0.2479 mL</td> <td>1.2394 mL</td> <td>2.4787 mL</td> </tr> </tbody> </table>	Solvent	Mass	Concentration			1 mg	5 mg	10 mg	Preparing Stock Solutions	1 mM	2.4787 mL	12.3937 mL	24.7874 mL	5 mM	0.4957 mL	2.4787 mL	4.9575 mL	10 mM	0.2479 mL	1.2394 mL	2.4787 mL
Solvent	Mass			Concentration																		
		1 mg	5 mg	10 mg																		
Preparing Stock Solutions	1 mM	2.4787 mL	12.3937 mL	24.7874 mL																		
	5 mM	0.4957 mL	2.4787 mL	4.9575 mL																		
	10 mM	0.2479 mL	1.2394 mL	2.4787 mL																		
	Please refer to the solubility information to select the appropriate solvent.																					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.5 mg/mL (6.20 mM); Suspended solution; Need ultrasonic																					

BIOLOGICAL ACTIVITY

Description	(4-NH ₂)-Exatecan, a topoisomerase inhibitor, is a derivative of Exatecan. (4-NH ₂)-Exatecan can be used in the synthesis of antibody-drug conjugates (ADCs) (US20200306243A1, compound A) ^[1] .
In Vitro	(4-NH ₂)-Exatecan contains a linker for connecting to a Ligand Unit, wherein the linker is attached in a cleavable manner to the amino residue, characterized by the addition of an amino (NH ₂) functional group at the 4th position of the parent molecule ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Howard PW, et, al. Compounds and conjugates thereof. US20200306243A1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA